Close mobile menu×
Close mobile menu

Kevin Kalinsky, MD, MS

Board Certifications: 
Medical Oncology, Internal Medicine
Expertise in: 
Cancer Care, Breast Cancer
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-5098

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

America's Top Doctor

Board Certifications

  • Medical Oncology
  • Internal Medicine

Clinical Expertise

  • Cancer Care
  • Breast Cancer

Specialties

Education & Training

  • MD, Medical University of South Carolina
  • Columbia University Mailman School of Public Health
  • Internship: Tufts Medical Center
  • Residency: Tufts Medical Center
  • Fellowship: Tufts Medical Center
  • Fellowship: Memorial Sloan-Kettering Cancer Center, NY

About Kevin Kalinsky

Kevin Kalinsky, M.D., M.S. is an Assistant Professor of Medicine at the NewYork-Presbyterian Hospital/Columbia University Medical Center. Dr. Kalinsky received his undergraduate B.A. from Emory University. He received his M.D. from the Medical University of South Carolina and completed his Internal Medicine internship and residency and Hematology/Oncology fellowship at Tufts Medical Center. In Boston, he also trained as a breast cancer clinical research fellow at Massachusetts General Hospital. In addition, he completed an advanced oncology fellowship in breast cancer at Memorial Sloan-Kettering Cancer Center. Since joining as a faculty member, Dr. Kalinsky completed a Master's program in Biostatistics, Patient–Oriented Research at Columbia.

Dr. Kalinsky cares for patients diagnosed with breast cancer and teaches on the Breast Oncology service. He was recently awarded the Ewig Clinical Scholar Teaching Award at Columbia. Dr. Kalinsky's research involves the development of early phase clinical trials to assess novel therapeutic agents in breast cancer based on tumor genomics. The goal of his research is to translate findings developed at the bench to clinical trials for study at the bedside. His work is funded by a number of sources, including the National Institute of Health and SWOG/Hope Foundation. He is a recipient of the 2017 NCI Cancer Clinical Investigator Team Leadership Award, as well as the Physician of Impact Award by Komen Greater NYC.

Academic Titles

  • Assistant Professor of Medicine at CUMC

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Medicare

  • Traditional Medicare (NY)

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
New York, New York 10032
Phone:
(212) 305-5098
Fax:
(212) 305-6891
Primary

Research

Grants

A PHASE I, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ESCALATING DOSES OF DHES0815A IN PATIENTS WITH HER2 POSITIVE BREAST CANCER (P&S Industry Clinical Trial)

Mar 20 2018 - Mar 20 2023

AN INTERNATIONAL, MULTICENTER ,OPEN LABEL, RANDOMIZED,PHASE III TRIALS OF SACITUZUMAB GOVITECAN VERSUS TREATMENT OF PHYSICOAN CHOICE IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER WHO RECEIVED AT LEAST TWO PRIOR TREATMENTS (P&S Industry Clinical Trial)

Jan 22 2018 - Jan 22 2023

A PHASE 1B STUDY OF TALIMOGENE LAHERPAREPVEC IN COMBINATION WITH ATEZOLIZUMAB IN SUBJECTS WITH TRIPLE NEGATIVE BREAST CANCER AND COLORECTAL CANCER WITH LIVER METASTASES. (P&S Industry Clinical Trial)

Aug 29 2017 - Aug 29 2022

A MULTICENTER PHASE 2 STUDY OF THE GLUTAMINASE INHIBITOR CB-839 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED TRIPLE NEGATIVE BREAST CANCER (TNBC) INCLUDING PATIENTS OF AFRICAN ANCESTRY AND NON- AFRICAN ANCESTRY (P&S Industry Clinical Trial)

Jul 5 2017 - Jul 5 2022

I-SPY2 TRIAL (INVESTIGATION OF SERIAL STUDIES TO PREDICT YOUR THERAPEUTIC RESPONSE WITH IMAGING AND MOLECULAR ANALYSIS 2): AN ADAPTIVE BREAST CANCER TRIAL DESIGN IN THE SETTING OF NEOADJUVANT CHEMOTHE (Private)

Apr 17 2017 - Apr 16 2022

A PHASE 1 STUDY OF THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING ORAL DOSES OF THE GLUTAMINASE INHIBITOR CB 839, AS SINGLE AGENT AND IN COMBINATION WITH STANDARD CHEMOTHERAPY IN PATIENTS WITH ADVANCED (P&S Industry Clinical Trial)

Mar 5 2015 - Mar 5 2020

MONITORING NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS WITH DYNAMIC OPTICAL TOMOGRAPHIC IMAGING (Private)

Nov 28 2017 - Nov 27 2019

A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 3 STUDY OF FULVESTRANT WITH OR WITHOUT LY2835219, A CDK 4/6 INHIBITOR, FOR WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (P&S Industry Clinical Trial)

Oct 9 2014 - Oct 9 2019

EXEMESTANE OR FULVESTRANT THERAPY IN POSTMENOPAUSAL WOMEN WITH ER+/HER2? ADVANCED OR METASTATIC BREAST CANCER THAT HAS PROGRESSED ON TREATMENT WITH EVEROLIMUS IN COMBINATION WITH EXEMESTANE OR FULVESTRANT (P&S Industry Clinical Trial)

Oct 7 2014 - Oct 7 2019

A RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF RUXOLITINIB OR PLACEBO IN COMBINATION WITH CAPECITABINE IN SUBJECTS WITH ADVANCED OR METASTATIC HER2-NEGATIVE BREAST CANCER (P&S Industry Clinical Trial)

Aug 8 2014 - Aug 8 2019

IDENTIFYING LEPTOMENINGEAL METASTASIS FROM BREAST CANCER UTILIZING A NOVEL IMMUNOCYTOCHEMICAL MICROFLUIDIC DEVICE (Federal Gov)

Jul 15 2016 - Jun 30 2019

CANCER CENTER SUPPORT GRANT (Federal Gov)

Jul 1 2014 - Jun 30 2019

PHASE I/II TRIAL OF RUXOLITINIB IN COMBINATION WITH TRASTUZUMAB IN METASTATIC HER2 POSITIVE BREAST CANCER (P&S Industry Clinical Trial)

May 29 2014 - May 29 2019

A PHASE 1B STUDY OF LY2835219 IN COMBINATION WITH ENDOCRINE THERAPIES FOR PATIENTS WITH HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE METASTATIC BREAST CANCER (P&S Industry Clinical Trial)

May 22 2014 - May 22 2019

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER 2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER 2+ DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA) (P&S Industry Clinical Trial)

May 14 2014 - May 14 2019

UNDERSTANDING BARRIERS TO QUALITY CANCER CARE (Private)

Oct 1 2017 - Sep 30 2018

: PRE-SURGICAL TRIAL OF METFORMIN AND ATORVASTATIN IN OPERABLE BREAST CANCER (Federal Gov)

Aug 1 2014 - Jul 31 2018

RANDOMIZED PHASE II STUDY OF FULVESTRANT VS. FULVESTRANT IN COMBINATION WITH BORTEZOMIB IN WOMEN WITH ER POSITIVE METASTATIC BREAST CANCER (P&S Industry Clinical Trial)

Jul 2 2013 - Jul 2 2018

A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, PHASE III STUDY TO COMPARE THE EFFICACY AND TOLERABILITY OF FULVESTRANT (FASLODEXTM) 500MG WITH ANASTROZOLE (ARIMIDEXTM) 1MG AS HORMONAL TREATMENT FOR POSTMENOPAUSAL WOMEN (FALCON) (P&S Industry Clinical Trial)

May 30 2013 - May 30 2018

AN OBSERVATIONAL COHORT STUDY OF TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH HER2 POSITIVE (HER2+) METASTATIC BREAST CANCER (P&S Industry Clinical Trial)

Jan 30 2013 - Jan 30 2018

BREAST CANCER ACCESS TO CARE AND DISPARITIES RESEARCH PROGRAM (Private)

Jan 1 2016 - Dec 31 2016

MASTER REGULATOR ANALYSIS TO PRIORITIZE TESTING OF PATIENT-DERIVED XENOGRAFTS TO IDENTIFY EFFECTIVE PRECISION TREATMENTS FOR PATIENTS WITH RESIDUAL DISEASE AFTER NEOADJUVANT BREAST CANCER BREAST CANCE (Private)

Jan 1 2015 - Dec 31 2016

SWOG-PURCHASE SERVICE AGREEMENT (Federal Gov)

Dec 10 2013 - Dec 9 2016

UNDERSTANDING BARRIERS TO QUALITY CANCER CARE (Private)

Oct 1 2015 - Sep 30 2016

20060359 (P&S Industry Clinical Trial)

Sep 8 2011 - Sep 8 2016

TARGETING COMPUTATIONALLY INFERRED MASTER REGULATORS IN PATIENT DERIVED XENOGRAFTS FROM PATIENTS WITH OPERABLE BREAST CANCER (Private)

Jul 1 2015 - Jun 30 2016

CLINICAL AND TRANSLATIONAL SCIENCE AWARD (Federal Gov)

Sep 30 2006 - Jun 30 2016

REDUCING OVERUSE, IMPROVING ADHERENCE AND UNDERSTANDING BARRIERS TO QUALITY CANCER CARE (Private)

Oct 1 2014 - Sep 30 2015

SHORT AND LONG TERM CONSEQUENCES OF BREAST CANCER TREATMENT (Private)

Oct 1 2013 - Sep 30 2014

SHORT AND LONG TERM CONSEQUENCES OF BREAST CANCER TREATMENT (Private)

Oct 1 2012 - Sep 30 2013

EVALUATING BLOOD-BASED BIOMARKERS IN PATIENTS TREATED WITH A N AKT INHIBITOR (MK-2206) IN A PRE-SURGICAL MODEL (Private)

Jul 1 2011 - Jun 30 2012

STUDIES IN CANCER SURVIVORSHIP (Private)

Oct 1 2010 - Dec 31 2011

PRE-SURGICAL INTERVENTION STUDY TO EVALUTE THE EFFECT OF MET ROMIN ON BREAST CANCER PROLIFERATION (Private)

Mar 1 2010 - Jul 31 2011

Selected Publications

Visit Pubmed for a full listing of Kevin Kalinsky’s journal Articles